Complex functions of mutant p53 alleles from human prostate cancer

被引:47
|
作者
Shi, XB
Nesslinger, NJ
Deitch, AD
Gumerlock, PH
White, RWD
机构
[1] Univ Calif Davis, Sch Med, Dept Urol, Sacramento, CA 95817 USA
[2] Univ Calif Davis, Sch Med, Dept Internal Med, Sacramento, CA 95817 USA
来源
PROSTATE | 2002年 / 51卷 / 01期
关键词
p53; prostate cancer; loss-of-function; dominant-negative; gain-of-function;
D O I
10.1002/pros.10072
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. Few studies have used multiple assays to examine the functionality of mutant p53 in prostate cancer (CaP). We employed seven functional assays to study 16 representative mutant p53 alleles, six from localized and ten from metastatic Cap. METHODS. Yeast assays were employed to determine loss of function (LOF), partial function (PF), and dominant-negative status, Assays using p53-null Saos2 cells were used to determine whether mammalian cells transfected with mutant p53 could up-regulate the MDR-1 or PCNA promoters, alter IL-6 expression or confer the ability to grow in soft agar. As a further test of gain of function (GOF) p53-null PC3 cells stably transfected. with these mutant p53 alleles were examined for cell cycle distributions. RESULTS. All 16 mutant p53 alleles demonstrated either total or partial LOR All but one allele also had at least one gain of function; however, the pattern of GOF was different for each mutant allele. Alleles derived from both localized and metastatic Cap had similar GOF characteristics; however, only alleles from metastatic disease had significantly increased S-phase fractions. CONCLUSIONS. Different mutant p53 alleles from Cap had different, complex functional profiles. The lack of predictable patterns for these alleles suggest that each mutation may uniquely affect p53 function. Prostate 51: 59-72, 2002. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:59 / 72
页数:14
相关论文
共 50 条
  • [21] p53 mutation in prostate cancer
    不详
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (02) : 105 - 105
  • [23] Mechanism of resistance to chemoradiation in p53 mutant human colon cancer
    Hiro, Junichiro
    Inoue, Yasuhiro
    Toiyama, Yuji
    Miki, Chikao
    Kusunoki, Masato
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2008, 32 (06) : 1305 - 1310
  • [24] Targeting Mutant p53 in Human Tumors
    Lehmann, Brian D.
    Pietenpol, Jennifer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3648 - 3650
  • [25] CANCER Mutant p53 and chromatin regulation
    Prives, Carol
    Lowe, Scott W.
    NATURE, 2015, 525 (7568) : 199 - 200
  • [26] Mutant p53 as a guardian of the cancer cell
    Mantovani, Fiamma
    Collavin, Licio
    Del Sal, Giannino
    CELL DEATH AND DIFFERENTIATION, 2019, 26 (02): : 199 - 212
  • [27] Mutant p53 as an Antigen in Cancer Immunotherapy
    Sobhani, Navid
    D'Angelo, Alberto
    Wang, Xu
    Young, Ken H.
    Generali, Daniele
    Li, Yong
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (11) : 1 - 21
  • [28] Mutant p53 as a guardian of the cancer cell
    Fiamma Mantovani
    Licio Collavin
    Giannino Del Sal
    Cell Death & Differentiation, 2019, 26 : 199 - 212
  • [29] Mutant p53 as a target for cancer treatment
    Duffy, Michael J.
    Synnott, Naoise C.
    Crown, John
    EUROPEAN JOURNAL OF CANCER, 2017, 83 : 258 - 265
  • [30] Targeting mutant p53 for cancer therapy
    Oren, Moshe
    Tal, Perry
    Rotter, Varda
    AGING-US, 2016, 8 (06): : 1159 - 1160